期刊文献+

磁性载药微球联合反义寡核苷酸对人胰腺癌裸鼠模型的疗效观察

Reversal of Multidrug Resistance Antisense Oligodeoxynucletedes and PEG-5-FU-MAMS for Human Pancreatic Carcinoma Model in Nude Mice
下载PDF
导出
摘要 目的探讨辐射促细胞转染的多药耐药(multidrug resistance,MDR)基因mdr1反义寡核苷酸(ASON)联合5-氟尿嘧啶磁性载药微球(PEG-5-FU-MAMS)治疗裸鼠人胰腺癌的效果。方法通过构建裸鼠人胰腺癌耐药肿瘤模型基础上,肿瘤局部以2 Gy^(60)Coγ辐射,瘤内注射阳性脂质体介导的mdr1反义寡核苷酸(ASON),经磁导下利用磁性载药微球(PEG-5-MAMS)联合化疗。结果联合辐射组与未联合辐射组及对照组肿瘤生长曲线肿瘤生长曲线差异有显著性(P<0.01)。联合组能显著抑制肿瘤的生长,联合组肿瘤重量抑制率为85.00%,肿瘤体积抑制率为87.74%。结论辐射促转染的mdr1ASON联合磁性载药微球对肿瘤细胞具有较好的耐药逆转作用。 Objective To investigate the efficacy of reversal of multidrug resisitance ( MDR) by MDR gene mdrl anti-sense oligodeoxynucletdes (ASON) and Polyethylene Glycol modified 5-Fluorouracil magnetic albumin miscrospheres (PEG-5-FU-MAMS) for the human pancreatic cancer cell line in SW 1990/Fu,and realize magnetic targeted therapy the human pancreatic cancer in nude mouse model .Methods dr1 ASON was injected into the tumor 1 hour after local 2 Gy60 Coγirradition.The tumor-suppressing rate and tumor-suppressing curve were observed in the 2 groups of cells after treatment with Polyethylene Glycol modified 5-Fluorouracil magnetic albumin miscrospheres (PEG-5-FU-MAMS).Results Significant differences in tumor weight and tumor volume were also observed between the 2 different treat group(P〈0.01).The suppressing rates of tumor volume and weight were 87.74%and 85.00%respectively in grouop accepted combined radiation .Conclusion The reversal effect of mdr1 ASON and ionizing radiation plus Polyethy-lene Glycol modified 5-Fluorouracil magnetic albumin miscrospheres ( PEG-5-FU-MAMS) is stronger on resistant cell than that of mdr 1 ASON and Polyethylene Glycol modified 5-Fluorouracil magnetic albumin miscrospheres(PEG-5-FU-MAMS) alone.
出处 《实用癌症杂志》 2017年第2期181-184,共4页 The Practical Journal of Cancer
基金 辽宁省自然科学基金(编号:201102006)
关键词 电离辐射 反义寡核苷酸 转染 多药耐药 PEG-5-FU-MAMS Ionizing radition Antisense Oligodeoxynuce-letides Gene transfection Multidrug resistance PEG-5-FU-MAMS
  • 相关文献

参考文献1

二级参考文献27

  • 1Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010[J]. CA Cancer J Clin, 2010, 60:277-300.
  • 2Pilepich MV, Miller HH. Preoperative irradiation in carcino- ma of the pancreas[J]. Cancer, 1980,46:1945-1949.
  • 3Lawrence TS, Chang EY, Hahn TM, et al. Radiosensitization of pancreatic cancer cells by 2' 2 '-difluoro-2 '-deoxycytidine [J]. Int ] Radiat Oneol Biol Phys, 1996,34:867-872.
  • 4Evans DB, Varadachary GR, Crane CH et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head[J]. J Clin Oncol, 2008, 26:3496 3502,.
  • 5Varadachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based che- moradiation for resectable adenocarcinoma of the pancreatic head[J]. J Clin Oncol, 2008,26:3487-3495.
  • 6McGinn CJ, Zalupski MM. Radiation therapy with once-week- ly gemcitabine in pancreatic cancer: current status of clinical trials[J]. Int J Radiat OncolBiol Phys, 2003, 56 (4 Suppl) 10-15.
  • 7McGinn CJ, Zalupski MM, Shureiqi 1, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gem- citahine in patients with advanced pancreatic cancer[M]. J Clin Oncol, 2001,19:4202-4208.
  • 8Talamonti MS, Jr. WS, Mulcahy MF, et al. A multi-institu- tional phase Ⅱ trial of preoperative full-dose gemeitabine and concurrent radiation for patients with potentially reseetable pancreatic carcinoma[J]. Ann Surg Oncol, 2006, 13 : 150-158.
  • 9Small Jr. W, Berlin J, Freedman GM, et al. Full-dose gemcit abine with concurrent radiation therapy in patients with non- metastatic pancreatic cancer., a multicenter phase Ⅱ trial[J]. J Clin Oncol, 2008,26:942-947.
  • 10Scodan RL, Mornex F, Girard N, et al. Preoperative chemo- radiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review [J]. Ann Oncol, 2009,20 : 1387-1396.

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部